You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Synthetic Universal Flu Vaccine

    SBC: TRIA BIOSCIENCE CORP.            Topic: NCIRD

    Abstract Type A and B Influenza viruses cause severe seasonal epidemics and less frequent but more deadly pandemic infectionsVaccination provides the best protectionalthough serious problems are confronting the global Influenza marketVirus diversity and mutation rates necessitate the annual production of hundreds of millions of vaccines using antiquated egg based technologiesCompounding this is th ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines

    SBC: HDT BIO CORP            Topic: NCIRD

    Project Summary SignificanceSinceavian influenza AH Nhas sickened overpeople with amortality rateHalf of all cases occurred inwhich also saw the emergence of a highly pathogenic strainThusH Navian influenza is poised to emerge as a devastating pandemic in a worldwide population that has no pre existing immunityCurrent Hvaccineswhether attenuatedinactivatedsplit or recombinantare insufficiently imm ...

    SBIR Phase I 2018 Department of Health and Human ServicesCenters for Disease Control and Prevention
  3. Enhanced Treatment Management of Opioid-Dependence in an Office-Based Setting

    SBC: MedicaSafe Inc            Topic: NIDA

    PROJECT SUMMARY ABSTRACT Opioid use disorder is the leading cause of accidental death in the USwith overlethal drug overdoses inSAMHSA estimates thatmillion Americans misuse prescription opioids for non medical purposes annuallyPublic health officials and policymakers have acknowledged the urgent need for innovative approaches to the treatment of those with opioid use disorderin spite of thisthe a ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Tau oligomer platform validation using lead series candidate in htau mice

    SBC: OLIGOMERIX INC            Topic: NIA

    TITLETau oligomer platform validation using lead series candidate in htau mice PROJECT SUMMARYSBIR Funding OpportunityAdvancing Research on Alzheimerandapos s DiseaseADand Alzheimerandapos s Disease Related DementiasADRDRRPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand related tauopathiesThere is a critical unmet need for a di ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Gene and Stem Cell-Based Treatment for Tendinopathy

    SBC: NEW YORK R & D CENTER FOR TRANSLATIONAL MEDICINE & THERAPEUTICS INC            Topic: R

    Project SummaryTendinopathy is a common chronic tendon disorder that affectsof individuals overyears oldIt is characterized by painswellingloss of functionand impaired performanceThere is currently no cure for tendinopathySpontaneous repair or treatment typically leads to scar formationresulting in a weakened tissue with reduced function and mechanical properties that may ultimately rupture with f ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD

    SBC: OLIGOMERIX INC            Topic: NIA

    PROJECT SUMMARYSBIR RRFast Track ApplicationFOA NumberPASThe long term goal of this program is to develop a disease modifyingsmall molecule drug for Alzheimer s diseaseADand AD related dementiasADRDwith tau pathologyThere is a critical unmet need for a disease modifying drugDMDfor ADChronic treatment strategies require safeeffectiveand economically feasible approaches such as small molecule drugsT ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 103

    Project Summary Sanfilippo disease (mucopolysaccharidosis type III; MPS III) is a devastating neurodegenerative lysosomal storage disorder of childhood whose pathologic features are neurologic: slowing of development, severe behavioral problems, progressive cognitive decline, dementia, and decline in motor skills leading to immobility, unresponsiveness, and death. We have focused on MPS IIID cause ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. High-throughput nanoMEA-based Proarrhythmia Assay

    SBC: CURI BIO, INC.            Topic: NHLBI

    PROJECT SUMMARY Failure of new drugs at late stages of development is an extremely costly event commonly associated with the detection of unexpected arrhythmogenic properties in novel drugs Undetected arrhythmia inducing effects are also a common reason for drug withdrawal from the market As a result the FDA now mandates that all new drugs be tested for potential arrhythmogenic properties which ha ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an advanced cryothermal ablation catheter and method for treating cardiac arrhythmias

    SBC: CELL PRESERVATION SERVICES INC            Topic: R

    The need for the development of new strategies for treatment of cardiac arrhythmiasincluding ventricular arrhythmiashas experienced a palpable increase in the last few yearsVentricular ArrhythmiaVAor ventricular tachycardiaVTis a severe abnormal heart rhythm which can cause death if not treated immediatelyVentricular FibrillationVFis the most serious form of VAVF is most commonly caused by VT and ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Preparation and development of a stabilized C3 analog for the treatment of paroxysmal nocturnal hemoglobinemia

    SBC: Cascade Biotechnology            Topic: NHLBI

    Abstract We propose to develop analogs of human complement Cthat have the ability to form a stable CconvertaseIn additionthese proteins will be designed to decrease the affinity of the proteins for factor H bindingAll proteins will be expressed in the Baculovirus insect protein expression systemand tested for their ability to form a stable Cconvertase enzyme that is able to deplete complement in h ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government